阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的长期真实世界结局
基于意大利ARTE数据库538例不可切除肝细胞癌患者的前瞻性真实世界研究,中位随访24.2个月,中位总生存期19.7个月,36个月生存率30.0%。≥3级不良事件发生率36.8%,14.1%患者发生非肿瘤进展性肝失代偿,4.4%患者达到无药无病状态。
要点
- 中位随访24.2个月,中位OS 19.7个月,36个月生存率30.0%
- ≥3级不良事件发生率36.8%,24个月后出现5例迟发性严重毒性
- 14.9%患者后续接受手术或局部治疗,4.4%达到无药无病状态
核心结论
- AB方案在真实世界中显示持续有效性且无新安全性信号
- 开始AB后手术/局部治疗和肝失代偿常见,需多学科整合管理
研究设计与样本
- 前瞻性真实世界队列研究,纳入意大利ARTE数据库538例接受AB治疗的不可切除HCC患者
主要发现
- 中位随访24.2个月,中位OS 19.7个月(95%CI 17.2-22.2),36个月生存率30.0%
- 影响OS的独立因素包括ECOG-PS>0、ALBI分级>1、AFP>400 ng/mL、多结节、大血管侵犯及治疗中事件
- ≥3级不良事件发生率36.8%,24个月后出现5例迟发性严重毒性
- 非肿瘤进展性肝失代偿发生率14.1%
临床怎么用
- AB治疗期间需监测肝失代偿和迟发性毒性
- 对适合患者应考虑后续手术或局部治疗以实现无药无病状态
- 晚期HCC管理应采纳多学科整合模式
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Unlike other immune-based combinations for hepatocellular carcinoma (HCC), long-term data for atezolizumab-bevacizumab (AB) are lacking, as the IMbrave150 trial closed after a median follow-up of 15.6 months. Consequently, reports of long-term outcomes for AB rely mainly on real-world evidence. We evaluated long-term effectiveness, safety, and clinically relevant on-treatment events in a large prospective real-world cohort of patients treated with AB. APPROACH AND RESULTS: We analyzed 538 patients prospectively enrolled in the Italian ARTE database. Outcomes included overall survival (OS), safety, liver decompensation, rate of patients achieving drug-free disease-free status. On-treatment events were modelled as time-dependent covariates in Cox regression models. After a median follow-up of 24.2 months, median OS was 19.7 months (95% CI 17.2-22.2), with a 36-month survival rate of 30.0%. Independent factors influencing OS included ECOG-PS >0, ALBI grade >1, AFP >400 ng/mL, multinodularity, macrovascular invasion, and on-treatment events (objective response, progression, or liver decompensation). Grade ≥3 AEs occurred in 36.8% of patients; 5 late-onset severe toxicities arose beyond 24 months. Liver decompensation unrelated to tumor progression occurred in 14.1% patients. Eighty patients (14.9%) underwent surgical or locoregional procedures after the initiation of AB; 24 (4.4%) achieved a drug-free disease-free status. CONCLUSIONS: Our data confirmed the sustained effectiveness of AB without new safety concerns. Surgical/locoregional treatments after the start of AB and liver decompensation were common, highlighting the need for a multidisciplinary and integrated approach in advanced HCC.
引用
- Tovoli F, Iavarone M, Cabibbo G, et al. Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study. Hepatology. 2026. PMID: 41746328. doi:10.1097/HEP.0000000000001725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。